Global Health Priorities: Eliminating Viral Hepatitis Healthcare Systems Guide

Viral hepatitis remains one of the most significant public health challenges of the twenty-first century. Despite being both preventable and, in many cases, curable, chronic infections caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV) continue to place an enormous burden on communities, medical infrastructure, and national budgets around the world. As health leaders look toward the World Health Organization (WHO) target of eliminating viral hepatitis as a major public health threat by 2030, national health agencies are re-evaluating their strategies, reallocating resources, and modernizing care pathways.

The global response to viral hepatitis has reached a pivotal juncture. While medical science has delivered highly effective vaccines, precision diagnostic tools, and revolutionary curative treatments, the gap between scientific capability and real-world implementation remains wide. Addressing this divide requires systemic transformation, cross-border collaboration, and sustained domestic investment. Examining how modern health infrastructure adapts to these demands reveals how global health priorities are shifting to combat chronic liver disease and prevent millions of avoidable deaths.

The Current Global Burden: 2026 Data and Realities

To understand the urgency of viral hepatitis elimination, one must look at the global disease burden. According to the latest WHO Global Hepatitis Report, approximately 287 million people worldwide are living with chronic viral hepatitis B or C. Together, HBV and HCV account for more than 95% of all hepatitis-related mortality, primarily through liver cirrhosis and primary liver cancer (hepatocellular carcinoma).

The data reflects both notable achievements and persistent vulnerabilities. On the progress front, global childhood vaccination programs have driven down hepatitis B transmission significantly. New chronic HBV infections have dropped by 32% globally since 2015, and 85 countries have achieved or surpassed the 2030 benchmark of reducing HBV prevalence in children under five years of age to 0.1% or lower. Additionally, direct-acting antiviral (DAA) therapies for hepatitis C have yielded a 12% reduction in HCV-related deaths over the past decade.

However, the overall trajectory reveals that global efforts remain off track to hit the ambitious 2030 targets. The burden of viral hepatitis is disproportionately concentrated in specific geographical regions and vulnerable populations. For instance, 68% of all new chronic HBV infections occur in the WHO African Region, where access to the crucial birth-dose vaccine remains severely limited. Furthermore, ten countries—including China, India, Indonesia, Nigeria, South Africa, and Viet Nam—account for nearly 69% of global HBV-related deaths. Addressing these disparities requires targeted interventions tailored to local epidemiological profiles.

Key Strategies for Eliminating Viral Hepatitis Healthcare Systems Must Adopt

Achieving global elimination requires comprehensive, multi-layered action plans. Forward-thinking medical networks are focusing on four primary pillars to dismantle barriers to care and scale up prevention.

1. Universal Immunization and Timely Birth-Dose Vaccines

The cornerstone of hepatitis B prevention is universal infant vaccination. The first dose of the hepatitis B vaccine—administered within 24 hours of birth—serves as a critical shield against perinatal transmission from mother to child. While global coverage for the three-dose infant series exceeds 80%, birth-dose coverage lags behind, particularly in sub-Saharan Africa, where only 17% of newborns receive timely vaccination. Healthcare providers are restructuring maternal and neonatal pathways to ensure that birth-dose immunization is integrated into all delivery facilities, including home-birth management protocols.

2. Strategic Micro-Elimination Programs

Rather than attempting sweeping, population-wide overhauls all at once, many countries are achieving rapid success through micro-elimination. This approach breaks down national elimination goals into manageable targets focused on specific populations, health settings, or geographic areas. Key priority groups include:

• Individuals in correctional facilities: High-density settings provide an opportunity for rapid test-and-treat programs.

• People who inject drugs (PWID): Integrating harm reduction services, such as needle and syringe programs, with point-of-care testing significantly reduces HCV transmission.

• Patients with chronic liver conditions or kidney disease: Routine screening in specialty clinics catches infections before irreversible damage occurs.

3. Decentralization and Integration into Primary Care

For decades, viral hepatitis testing and management were restricted to specialized tertiary hospitals and hepatology centers. This centralized model created geographic and financial bottlenecks for patients. Leading healthcare networks are decentralizing hepatitis care by shifting task-shifting responsibilities to primary care physicians, community nurses, and local health workers. By integrating rapid diagnostic tests (RDTs) into routine primary health clinic visits, patients can receive a diagnosis and treatment plan in a single visit.

4. Treatment Scale-Up and Price Optimization

The introduction of pan-genotypic Direct-Acting Antivirals (DAAs) transformed hepatitis C management, offering a cure rate exceeding 95% with a simple 8-to-12-week oral regimen. For hepatitis B, long-term antiviral therapies effectively suppress viral replication and reduce liver cancer risk. Health ministries are leveraging voluntary licensing, generic manufacturing, and pooled procurement mechanisms to dramatically lower drug costs, making cure and management accessible in low- and middle-income countries.

Critical Gaps and Challenges in the Response

Despite technological advances, systemic hurdles continue to impede global progress. Identifying and addressing these structural bottlenecks is essential for maintaining momentum toward 2030 goals.

The Severe Testing and Treatment Gap

The most glaring vulnerability in the global response is the sheer volume of undiagnosed and untreated individuals. Current estimates indicate that less than 5% of people eligible for hepatitis B treatment are actively receiving therapy. Similarly, only 20% of people diagnosed with hepatitis C have received curative DAA treatment since 2015. Millions of individuals remain unaware of their infection status due to the silent, asymptomatic nature of early-stage chronic liver disease, presenting to medical facilities only after developing advanced cirrhosis or liver cancer.

Funding Shortfalls and Domestic Investment Constraints

Unlike other major infectious threats—such as HIV/AIDS, tuberculosis, and malaria—viral hepatitis has historically lacked dedicated international donor funding mechanisms. Most national hepatitis programs rely almost entirely on domestic budgetary allocations. In countries facing broader economic constraints, funding for viral hepatitis screening, public awareness campaigns, and harm-reduction infrastructure is frequently deprioritized.

Harm Reduction Deficits

Unsafe injection practices in healthcare settings and substance use remain primary drivers of new HCV transmission. Globally, people who inject drugs account for nearly 44% of new hepatitis C infections. However, access to comprehensive harm-reduction services—such as sterile syringe distribution and opioid agonist therapy—remains far below target levels in most regions, leaving vulnerable communities exposed to repeated infection.

Innovations and Future Outlook to 2030

The path to 2030 depends heavily on deploying innovative technologies and streamlined clinical protocols. Point-of-care viral load testing devices now allow clinicians to confirm active infection within hours rather than weeks, dramatically reducing patient drop-off between screening and treatment initiation.

Simplified clinical guidelines released by the WHO have streamlined treatment eligibility, allowing non-specialist healthcare workers to initiate treatment without requiring complex, expensive staging equipment like FibroScan or invasive liver biopsies. At the same time, biomedical research continues to advance toward a functional cure for hepatitis B, with novel therapeutic classes—including gene-editing tools, antisense oligonucleotides, and entry inhibitors—currently undergoing clinical trials.

Ultimately, eliminating viral hepatitis is not merely a clinical objective; it is a catalyst for strengthening overall global health security, reducing health inequities, and achieving universal health coverage.

Frequently Asked Questions (FAQ)

Why is eliminating viral hepatitis healthcare systems' major global priority?

For healthcare systems, eliminating viral hepatitis is a top priority because chronic HBV and HCV infections cause widespread premature mortality from liver cirrhosis and cancer. By scaling up early screening, vaccination, and treatment, health networks can prevent millions of deaths while relieving severe long-term financial burdens on oncology and organ transplant services.

What is the difference between Hepatitis B and Hepatitis C?

Hepatitis B is caused by HBV and is preventable through a highly effective vaccine. While it cannot be completely cured in most chronic cases, viral replication can be controlled with daily long-term medication. Hepatitis C is caused by HCV and currently has no preventative vaccine, but it can be completely cured in 8 to 12 weeks using oral Direct-Acting Antiviral (DAA) pills.

How do direct-acting antivirals contribute to hepatitis C elimination?

Direct-acting antivirals (DAAs) target specific viral proteins to block HCV replication. With cure rates exceeding 95% and minimal side effects, DAAs eliminate the virus from the body, stopping liver disease progression and preventing onward transmission to others.

Why is the birth-dose vaccine so critical for Hepatitis B prevention?

Mother-to-child transmission during childbirth is the primary pathway through which hepatitis B becomes a lifelong chronic infection. Administering the hepatitis B vaccine within 24 hours of birth creates an immediate defense, reducing the risk of infant infection by over 90%.

Take Action: Join the Global Push Against Viral Hepatitis

Eliminating viral hepatitis requires coordinated commitment from healthcare organizations, policy creators, medical personnel, and community advocates worldwide. Whether you are a healthcare professional updating your clinical screening protocols, a policymaker championing domestic health investments, or an individual seeking testing for yourself and your family, your involvement drives measurable progress.

To explore international guidelines, access educational resources, or support elimination campaigns, visit these trusted global health institutions:

• Learn more about global strategy and data at the World Health Organization Viral Hepatitis Hub.

• Discover patient advocacy tools and community action campaigns through the World Hepatitis Alliance.

• Access clinical guidelines and educational materials from the Centers for Disease Control and Prevention Viral Hepatitis Resource Center.